The Upstream-Downstream Health Lens
Classify health opportunities by prevention or sick care before investing
- Difficulty
- Easy
- Time to result
- ~days to results
- Steps
- 4
- Confidence
- 82%
The Upstream-Downstream Health Lens begins by splitting health opportunities into two broad directions. Upstream companies aim to prevent illness, improve habits, or optimise health before acute care is needed. Downstream companies serve people who are already sick or operate inside clinical care. Classifying a deal first clarifies the problem, customer, evidence, and payment environment that diligence should examine. An investor can then compare like with like, spot concentration in one side of the market, and deliberately maintain exposure to both. The lens is a map, not an investment verdict: product performance, founder quality, market structure, and economics still decide whether a company deserves capital. Armstrong used point-of-care diagnostics as a downstream example and Eternal as an optimisation-oriented health investment.
Origin
While explaining Next Ventures, Armstrong said health investing can be viewed simply as upstream preventative care and downstream sick care, with the fund willing to invest in both.
Core principles
- 01Reduce a broad market to two distinct care directions
- 02Treat prevention and sick care as different opportunity sets
- 03Allow a portfolio to participate on both sides
- 04Evaluate the founder and working product within the chosen side
How to run it
- 1
Define the Health Job
State the concrete health outcome the company produces and for whom. Avoid starting with the company's preferred category label.
Pro tip Describe the user, intervention, and expected outcome in one sentence.
Watch out A vague promise to improve health is not enough to classify or diligence a deal.
- 2
Place It Upstream or Downstream
Classify the main use case as preventative or optimisation-oriented upstream care, or as treatment and sick care downstream. Use the primary use case when a company touches both.
Pro tip Ask when in the patient's journey the product creates its main value.
Watch out Do not force a hybrid company into whichever side makes the pitch sound more attractive.
- 3
Apply Side-Specific Diligence
Examine the evidence, buyer, adoption path, and economics appropriate to that side of health. Confirm that the product actually works in the claimed setting.
Pro tip For clinical claims, separate demonstrated performance from a familiar-sounding story.
Watch out The two-side label is not evidence of efficacy.
- 4
Balance the Portfolio View
Review how the candidate changes exposure across upstream and downstream care. Decide whether the opportunity merits investment on its own and fits the portfolio's intended mix.
Pro tip Track opportunity quality and portfolio balance as separate judgements.
Watch out Do not fund a weak deal merely to fill an allocation bucket.
In the wild
Next Ventures invested in Vital Bio, which Armstrong described as providing fast lab testing in a doctor's office. The product sits downstream because it operates in a clinical setting around diagnosing and caring for patients.
→ The lens identifies the company as a downstream care opportunity requiring clinical and point-of-care diligence.
The fund's investment in Eternal represents the other side of the map: a company Armstrong associated with optimisation and a broader societal shift in attitudes toward health. Founder quality remained a separate reason for conviction.
→ The deal adds upstream or optimisation exposure without confusing category placement with the final investment case.
Common mistakes
Treating the map as the verdict
Knowing which side a company occupies does not prove that its product works or that its economics justify an investment.
Ignoring the primary use case
Classifying a company by a secondary feature can obscure where it actually creates value and which diligence questions matter.
Is it for you?
Best for
It is best for early-stage investors screening opportunities across consumer health and healthcare delivery.
Not ideal for
It is not ideal as a complete diligence process because classification alone does not establish product efficacy or investment quality.
From the transcript
“if you think about in health and you think about investing in health and you can look at it in a simple way really two…”
“we will dabble in both of those”
From the episode
Episode 471: Lance Armstrong: The Real Doping Story, $100M Loss, and His Venture Capital Comeback
Lance Armstrong